How can targeting hTERT in glioblastomas enhance treatment efficacy and reduce tumor recurrence?
DOI:
https://doi.org/10.58445/rars.2179Keywords:
Glioblastoma, Efficacy, Treatment, hTERT, RecurrenceAbstract
This paper looks at the potential of targeting hTERT to treat glioblastoma. hTERT is a protein that helps elongate DNA ends. Glioblastoma is an aggressive and malignant brain cancer. The hTERT promoter mutation is common among glioblastoma and other cancers and causes the overproduction of hTERT, which gives the tumor traits like rapid proliferation, resistance to treatment, and an immunosuppressive environment. hTERT is targeted by treatments like immunotherapy, DNA vaccines, inhibitors, and CRISPR. All of these are promising options for treating cancers like glioblastoma, but they also have limits and challenges. Targeting hTERT could also and already has helped treat other cancers and related diseases.
References
AANS. “Glioblastoma Multiforme.” AANS, https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/. Accessed 15 Oct. 2024.
Aquilanti, Elisa, et al. “Telomerase as a Therapeutic Target in Glioblastoma.” Neuro-Oncology, vol. 23, no. 12, Dec. 2021, pp. 2004–13. Silverchair, https://doi.org/10.1093/neuonc/noab203.
Chehelgerdi, Mohammad, et al. “Comprehensive Review of CRISPR-Based Gene Editing: Mechanisms, Challenges, and Applications in Cancer Therapy.” Molecular Cancer, vol. 23, Jan. 2024, p. 9. PubMed Central, https://doi.org/10.1186/s12943-023-01925-5.
D’Alessandris, Quintino Giorgio, et al. “Telomerase Inhibition in Malignant Gliomas: A Systematic Review.” Expert Reviews in Molecular Medicine, vol. 25, Jan. 2023, p. e10. Cambridge University Press, https://doi.org/10.1017/erm.2023.6.
Dana Foundation. “Cells of the Brain (Grades 9-12).” Dana Foundation, https://dana.org/resources/cells-of-the-brain-grades-9-12/. Accessed 14 Oct. 2024.
Davis, Mary Elizabeth. “Glioblastoma: Overview of Disease and Treatment.” Clinical Journal of Oncology Nursing, vol. 20, no. 5, Oct. 2016, pp. S2–8. PubMed Central, https://doi.org/10.1188/16.CJON.S1.2-8.
Di Nunno, Vincenzo, et al. “The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?” Cells, vol. 13, no. 1, 1, Jan. 2024, p. 44. www.mdpi.com, https://doi.org/10.3390/cells13010044.
Edelman, Martin J., et al. “Phase I and Pharmacokinetic Evaluation of the Anti-Telomerase Agent KML-001 with Cisplatin in Advanced Solid Tumors.” Cancer Chemotherapy and Pharmacology, vol. 78, no. 5, Nov. 2016, pp. 959–67. PubMed, https://doi.org/10.1007/s00280-016-3148-x.
Giunco, S., et al. “Prognostic Role and Interaction of TERT Promoter Status, Telomere Length and MGMT Promoter Methylation in Newly Diagnosed IDH Wild-Type Glioblastoma Patients.” ESMO Open, vol. 8, no. 3, June 2023, p. 101570. ScienceDirect, https://doi.org/10.1016/j.esmoop.2023.101570.
Hackett, Jennifer A., and Carol W. Greider. “Balancing Instability: Dual Roles for Telomerase and Telomere Dysfunction in Tumorigenesis.” Oncogene, vol. 21, no. 4, Jan. 2002, pp. 619–26. www.nature.com, https://doi.org/10.1038/sj.onc.1205061.
Hassanein, Nada. “New Way for States to Cover Pricey Gene Therapies Will Start with Sickle Cell Disease • Stateline.” Stateline, 14 Mar. 2024, https://stateline.org/2024/03/14/new-way-for-states-to-cover-pricey-gene-therapies-will-start-with-sickle-cell-disease/.
Krause, Michael. “Chapter 20 Transcription and Translation.” Methods in Cell Biology, edited by Henry F. Epstein and Diane C. Shakes, vol. 48, Academic Press, 1995, pp. 483–512. ScienceDirect, https://doi.org/10.1016/S0091-679X(08)61400-4.
Max-Planck-Gesellschaft. Structure of the CRISPR Sequence. https://www.mpg.de/11823627/crispr-cas9-palindromes-structure. Accessed 22 Dec. 2024.
Mayo Clinic. “Glioblastoma - Symptoms and Causes.” Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/glioblastoma/symptoms-causes/syc-20569077. Accessed 15 Oct. 2024.
Mizukoshi, Eishiro, and Shuichi Kaneko. “Telomerase-Targeted Cancer Immunotherapy.” International Journal of Molecular Sciences, vol. 20, no. 8, Apr. 2019, p. 1823. PubMed Central, https://doi.org/10.3390/ijms20081823.
Moffitt. “Recurrent Glioblastoma.” Moffitt, https://www.moffitt.org/cancers/glioblastoma/recurrence/. Accessed 24 Dec. 2024.
myTomorrowsTeam. “Understanding Glioblastoma Recurrence, Symptoms and Treatment Options.” myTomorrows, 19 July 2023, https://mytomorrows.com/blog/patients/understanding-glioblastoma-recurrence-and-treatment-options/.
National Brain Tumor Society. “About Glioblastoma.” National Brain Tumor Society, https://braintumor.org/events/glioblastoma-awareness-day/about-glioblastoma/. Accessed 14 Oct. 2024.
National Cancer Institute. Recurrent Cancer - NCI. 18 Jan. 2016, https://www.cancer.gov/types/recurrent-cancer. nciglobal,ncienterprise.
Pennisi, Giovanni, et al. “Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review.” International Journal of Molecular Sciences, vol. 25, no. 16, Aug. 2024, p. 8700. PubMed Central, https://doi.org/10.3390/ijms25168700.
Sava, Jordyn. “RZ-001 Gains FDA Fast Track Designation in Glioblastoma.” Targeted Oncology, 10 Nov. 2023, https://www.targetedonc.com/view/rz-001-gains-fda-fast-track-designation-in-glioblastoma.
Tao, Hong-yu, et al. “Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics.” International Journal of Nanomedicine, vol. 19, Apr. 2024, pp. 3805–25. PubMed Central, https://doi.org/10.2147/IJN.S448556.
Wang, Yu, et al. “Clinical Research Progress of Telomerase Targeted Cancer Immunotherapy: A Literature Review.” Translational Cancer Research, vol. 13, no. 7, July 2024. tcr.amegroups.org, https://doi.org/10.21037/tcr-24-196.
---. “Clinical Research Progress of Telomerase Targeted Cancer Immunotherapy: A Literature Review.” Translational Cancer Research, vol. 13, no. 7, July 2024, pp. 3904–21. PubMed Central, https://doi.org/10.21037/tcr-24-196.
Yan, Siyu, et al. “Regulation of Telomerase towards Tumor Therapy.” Cell & Bioscience, vol. 13, no. 1, Dec. 2023, p. 228. Springer Link, https://doi.org/10.1186/s13578-023-01181-6.
Yang, Ruozhu, et al. “Regulation and Clinical Potential of Telomerase Reverse Transcriptase (TERT/hTERT) in Breast Cancer.” Cell Communication and Signaling, vol. 21, no. 1, Aug. 2023, p. 218. Springer Link, https://doi.org/10.1186/s12964-023-01244-8.
Zhao, Gaoxiang, et al. “Base Editing of the Mutated TERT Promoter Inhibits Liver Tumor Growth.” Hepatology (Baltimore, Md.), vol. 79, no. 6, June 2024, pp. 1310–23. PubMed, https://doi.org/10.1097/HEP.0000000000000700.
Downloads
Posted
Categories
License
Copyright (c) 2025 Pranav Challa
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.